Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors
作者:Sundeep Kadasi、Thadeu E.M.M. Costa、Neha Arukala、Mallika Toshakani、Chaitanya Duggineti、Sreekanth Thota、Sayan D. Gupta、Shiva Raj、Carmen Penido、Maria G. Henriques、Nulgumnalli M. Raghavendra
DOI:10.2174/1573406413666170623085534
日期:2018.1.11
Background: Heat shock protein 90 is a molecular chaperone required for the stability and
function of several client proteins that promote cancer cell growth and/or survival. Discovery of Hsp90
inhibitors has emerged as an attractive target of research in cancer therapeutics. Natural products like
geldanamycin and radicicol are established Hsp90 inhibitors, but face limitations with toxicity and inactivity,
by in vivo studies respectively. However, they lay the logical starting point for the design of
novel synthetic or semi-synthetic congeners as Hsp90 inhibitors.
Objective: In this article, the structure based drug design of substituted 2-aryl/heteroarylidene-6-
hydroxybenzofuran-3(2H)-one analogues to optimize and mimic the pharmacophoric interactions of
the valid Hsp90 inhibitor radicicolis focused.
Method: In silico docking study was performed by Surflex dock-Geom (SYBYL- X 1.2 drug discovery
suite) and the designed ligands were chemically synthesized by conventional method using resorcinol
and chlororesorcinol as starting materials. Two dimensional chemical similarity search was carried
out to identify the chemical space of ‘SY' series in comparison with reported Hsp90 inhibitors.
The in vitro cell proliferation assay (resazurin reduction method) and proteomic investigation
(DARTS) was carried out on whole cell lysate to evaluate anticancer activity.
Results: The chemical structures of all the synthesized compounds were confirmed by IR, 1H-NMR and
Mass spectral analysis. The results of chemical similarity search show that SY series fit it in the chemical
space defined by existing Hsp90 inhibitors. In vitro cell proliferation assay, against human melanoma and
breast cancer cell lines, identified ‘SY3' as the promising anticancer agent amongst the series.
Conclusion: Docking studies, 2D chemical similarity search, resazurin reduction assay and qualitative
proteomic analysis identify ‘SY3’as a promising Hsp90 inhibitor amongst the series.
背景:热休克蛋白90是一种分子伴侣,参与多种促进癌细胞生长和/或存活的目标蛋白的稳定性和功能。Hsp90抑制剂的发现已成为癌症治疗研究中的一个有吸引力的目标。天然产物如胶丹霉素和雷地西酮已被确立为Hsp90抑制剂,但在体内研究中面临着毒性和无活性等限制。然而,它们为设计新型合成或半合成的相关化合物作为Hsp90抑制剂奠定了逻辑起点。
目标:本文聚焦于取代的2-芳基/杂芳基-6-羟基苯并呋喃-3(2H)-酮类似物的结构基础药物设计,以优化和模拟有效Hsp90抑制剂雷地西酮的药效团相互作用。
方法:通过Surflex dock-Geom (SYBYL-X 1.2药物发现套件)进行虚拟对接研究,设计的配体通过传统方法合成,使用对苯二酚和氯对苯二酚作为起始材料。进行二维化学相似性搜索,以识别与已报道Hsp90抑制剂相比的'SY'系列化学空间。采用体外细胞增殖测定(重氮还原法)和蛋白质组学研究(DARTS)对全细胞裂解液进行评估,以评估抗癌活性。
结果:所有合成化合物的化学结构通过红外光谱、1H-NMR和质谱分析得到确认。化学相似性搜索的结果表明,SY系列符合现有Hsp90抑制剂所定义的化学空间。在针对人黑色素瘤和乳腺癌细胞系的体外细胞增殖测定中,'SY3'被识别为该系列中有前景的抗癌剂。
结论:对接研究、二维化学相似性搜索、重氮还原测定和定性蛋白组学分析都确认了'SY3'作为该系列中有前景的Hsp90抑制剂。